Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

SynCardia provides the only FDA approved total artificial heart and a foundation for next generation fully implantable solutions.

What problem does Picard Medical solve?

Picard Medical / SynCardia is addressing one of the largest and fastest growing unmet needs in cardiovascular medicine. The Company’s SynCardia Total Artificial Heart replaces the circulatory functions of a failing human heart, sustaining patients who would otherwise not survive while they wait for a donor organ.

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

Unlike ventricular assist devices that support a weakened native heart, the SynCardia Total Artificial Heart fully replaces the heart’s pumping function and provides complete circulatory support. SynCardia’s technology is the only FDA approved total artificial heart available today, supported by established clinical use, reimbursement, and a growing global implant base.

As transplant waiting lists grow and organ supply remains limited, solutions that sustain patients long enough to receive a donor heart are becoming increasingly important in cardiac care. The Company is focused on scaling this platform while advancing next generation fully implantable solutions designed to expand life supporting opportunities for heart failure patients the market and improve patient outcomes.

‍

For more information on Picard Medical (NYSE: PMI) please click on the request investor info button.

‍

No items found.

You might also like

Yukon Metals: Exploring the Gap in North America’s Mineral-Rich Trend
Metals & Mining
October 14, 2026

Yukon Metals: Exploring the Gap in North America’s Mineral-Rich Trend

Across the Americas, major mineral systems follow recognizable geological trends. Yukon Metals is exploring what could lie within a compelling gap in that pattern.

This is some text inside of a div block.
Altamira Gold: Can a 2-Million-Ounce Gold Project Keep Growing in Brazil?
Metals & Mining
October 14, 2026

Altamira Gold: Can a 2-Million-Ounce Gold Project Keep Growing in Brazil?

Altamira Gold has grown its gold project in central-western Brazil to approximately 2 million ounces, with continued exploration focused on demonstrating the potential for a larger multimillion-ounce gold district.

This is some text inside of a div block.
CEO Clip - Altamira Gold: Can a 2-Million-Ounce Gold Project Grow Into a Larger District in Brazil?
Metals & Mining
October 14, 2026

CEO Clip - Altamira Gold: Can a 2-Million-Ounce Gold Project Grow Into a Larger District in Brazil?

Altamira Gold is advancing a growing gold project in central-western Brazil, where continued resource growth at the Maria Bonita porphyry discovery is supporting the company’s vision for a multimillion-ounce gold district.

This is some text inside of a div block.
Subscribe and receive the investor Info